Medications not yet evaluated by P&T are considered NON-FORMULARY. Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step!
Please be sure to document all clinical activities daily.
Search results for:

bebtelovimab

bebtelovimab
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Bebtelovimab SOLUTION, INJECTABLE 87.5 mg/mL      
Comments:

11/30/2022: Bebtelovimab is not currently authorized for emergency use in the U.S. because it is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1.

 

Use as investigational drug under national emergency declaration for the treatment for COVID-19 patients who meet the FDA's EUA and Huntsville Hospital's Criteria for Use.

Reviewed: Feb. 2022 (Betelovimab)

Updated: December 2022

Last updated: Apr. 26, 2023






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2026 Rpharmy, LLC ­ All Rights Reserved